Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma

Tumor mutation burdens (TMBs) act as an indicator of immunotherapeutic responsiveness in various tumors. However, the relationship between TMBs and immune cell infiltrates in hepatocellular carcinoma (HCC) is still obscure. The present study aimed to explore the potential diagnostic markers of TMBs...

Full description

Bibliographic Details
Main Authors:	Yulan Zhao, Ting Huang, Pintong Huang
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Diagnostics
Subjects:	hepatocellular carcinoma tumor mutation burden immune cells The Cancer Genome Atlas CIBERSORT
Online Access:	https://www.mdpi.com/2075-4418/12/8/1918

Similar Items

Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma
by: Mary Wong, et al.
Published: (2021-12-01)

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
by: Ioannis A. Voutsadakis
Published: (2022-02-01)

The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study
by: Junzhang Huang, et al.
Published: (2024-11-01)

Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma
by: Mingjun Xu, et al.
Published: (2021-11-01)

A novel prognostic model based on AFP, tumor burden score and Albumin-Bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation
by: Jingzhi Huang, et al.
Published: (2023-12-01)

Elucidating the role of SLC4A7 in glioma prognosis: A comprehensive approach combining bioinformatics, single-cell analysis, and tissue validation
by: Tung Liu, et al.
Published: (2023-01-01)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
by: Nai-Wen Kang, et al.
Published: (2021-11-01)

Assessment of Tumor Burden Score as a Feasible and Reliable Tool for Prognosis Prediction for Hepatocellular Carcinoma Undergoing Hepatectomy: A Multicenter, Retrospective Study
by: Guan R, et al.
Published: (2025-02-01)

LARS1 is a Prognostic Biomarker and Exhibits a Correlation with Immune Infiltrates in Hepatocellular Carcinoma
by: Fan L, et al.
Published: (2024-05-01)

CDKL3 is a promising biomarker for diagnosis and prognosis prediction in patients with hepatocellular carcinoma
by: Qingsi Wu, et al.
Published: (2024-06-01)

TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma
by: Yu-Jie Xu, et al.
Published: (2024-07-01)

BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers
by: Huiping Shi, et al.
Published: (2024-01-01)

Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score
by: Jiawei Lin, et al.
Published: (2024-03-01)

TRIP13 overexpression in hepatocellular carcinoma: implications for poor prognosis and immune cell infiltration
by: Jiapeng Xue, et al.
Published: (2023-09-01)

Identification of BAP1 mutation as a common mutation correlated with tumor mutation burden and immune infiltration in kidney renal clear cell carcinoma
by: Jin-Zhou Xu, et al.
Published: (2022-12-01)

The tumor burden score may be a discriminator in microwave ablation versus liver resection for hepatocellular carcinoma within the Milan criteria: a propensity score matching and inverse probability of treatment weighting study
by: Zeyuan Wei, et al.
Published: (2024-02-01)

Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations
by: Tomoko Aoki, et al.
Published: (2023-10-01)

Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma
by: Yuhong Huang, et al.
Published: (2024-02-01)

The role of neopterin in cross-talk between tumor and tumor microenvironment in hepatocellular carcinoma
by: Satılmış Basri, et al.
Published: (2024-11-01)

Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA
by: Abdalla Aly, et al.
Published: (2021-09-01)

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN
by: Saori Mishima, et al.
Published: (2023-09-01)

Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study
by: Qian-Ming Xiang, et al.
Published: (2023-10-01)

Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis
by: Juan P. Rodrigo, et al.
Published: (2024-02-01)

Prediction of Responses of Patients with Hepatocellular Carcinoma to Anti-PD-1 Immunotherapy by T-cell Invigoration to Tumour Burden Ratio
by: WU Hui, et al.
Published: (2023-11-01)

CAN008 prolongs overall survival in patients with newly diagnosed GBM characterized by high tumor mutational burden
by: Ian Yi-Feng Chang, et al.
Published: (2024-08-01)

Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
by: Mark Lee, et al.
Published: (2020-01-01)

Systematic analyses of a novel lncRNA‐associated signature as the prognostic biomarker for Hepatocellular Carcinoma
by: Jing Sui, et al.
Published: (2018-07-01)

Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6/CXCR2 in Hepatocellular Carcinoma
by: Hsin-Lun Lee, et al.
Published: (2023-07-01)

Identification of a prognostic signature of nine metabolism-related genes for hepatocellular carcinoma
by: Chaozhi Tang, et al.
Published: (2020-09-01)

Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study☆
by: Dongdong Xia, et al.
Published: (2025-01-01)

Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma
by: Yuanfei Lu, et al.
Published: (2022-08-01)

Prognostic relevance of sarcopenia and tumor‐infiltrating CD8+ T cells in patients with hepatocellular carcinoma
by: Shunsuke Doi, et al.
Published: (2025-03-01)

Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma
by: Cecilia Lezcano, et al.
Published: (2024-12-01)

Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma
by: Li Z, et al.
Published: (2023-11-01)

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
by: Xiaobin Zheng, et al.
Published: (2023-07-01)

Targeted inhibition of purine metabolism is effective in suppressing hepatocellular carcinoma progression
by: Chong, Yong Chun, et al.
Published: (2020)

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine
by: Célia Dupain, et al.
Published: (2024-02-01)

Synchronous Double Primary Tumors of Liver (Small Cell Neuroendocrine Carcinoma and Hepatocellular carcinoma): A Case Report
by: Bu Y, et al.
Published: (2024-04-01)

HBX Multi‐Mutations Combined With Traditional Screening Indicators to Establish a Nomogram Contributes to Precisely Stratify the High‐Risk Population of Hepatocellular Carcinoma
by: Chao‐Jun Zhang, et al.
Published: (2025-03-01)

Gene Expression Profiles Infer — The Landscape of Tumor-Infiltrating Immune Cells in Ovarian Cancer and their Clinical Significance
by: Caiyun Ding, et al.
Published: (2024-05-01)